home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490501.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
2KB
|
32 lines
Document 0501
DOCN M9490501
TI Levels of dapsone and pyrimethamine in serum during once-weekly dosing
for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic
encephalitis.
DT 9411
AU Opravil M; Joos B; Luthy R; Division of Infectious Diseases, University
Hospital, Zurich,; Switzerland.
SO Antimicrob Agents Chemother. 1994 May;38(5):1197-9. Unique Identifier :
AIDSLINE MED/94346835
AB Concentrations of dapsone, monoacetyldapsone, and pyrimethamine were
determined in 36 serum samples from human immunodeficiency
virus-infected patients on prophylaxis with once-weekly administration
of dapsone-pyrimethamine (200 mg of dapsone-75 mg of pyrimethamine).
During day 1 after ingestion, median levels of 1,038 ng of dapsone per
ml and 356 ng of pyrimethamine per ml were found. During days 6 to 7,
the dapsone level fell to < 20 ng/ml in five of nine serum samples, but
the pyrimethamine level remained elevated (125 ng/ml). Concurrent, but
separately ingested, didanosine administration did not seem to decrease
the drug concentrations.
DE Adult Aged Dapsone/ANALOGS & DERIVATIVES/ADMINISTRATION &
DOSAGE/*BLOOD/ *THERAPEUTIC USE Drug Interactions Female Human HIV
Infections/COMPLICATIONS/*METABOLISM Male Middle Age Phenotype
Pneumonia, Pneumocystis carinii/*PREVENTION & CONTROL
Pyrimethamine/ADMINISTRATION & DOSAGE/*BLOOD/*THERAPEUTIC USE Support,
Non-U.S. Gov't Toxoplasmosis, Cerebral/*PREVENTION & CONTROL
Zidovudine/ADVERSE EFFECTS/THERAPEUTIC USE JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).